Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Not stated	2026-04-13		NCT06062537

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Intergroupe Francophone du Myelome	7
Janssen-Cilag Ltd.	14

31 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Henri Becquerel	Rouen	France	71
Centre hospitalier d'Argenteuil	Argenteuil	France	1
Centre hospitalier de Brive-la-Gaillarde	Brive-la-Gaillarde	France	1
Centre Hospitalier Métropole de Savoie	Chambéry	France	3
CH Bretagne Atlantique	Vannes	France	5
CH d'ANNECY	Annecy	France	2
CH de METZ	Metz	France	1
CH Dunkerque	Dunkirk	France	4
CH Perpignan	Perpignan	France	5
CHU Amiens Picardie	Amiens	France	31
CHU Bordeaux	Bordeaux	France	1
CHU Caen	Caen	France	48
CHU Clermont-Ferrand Site Estaing	Clermont-Ferrand	France	1
CHU de Besançon	Besançon	France	26
CHU de Lille	Lille	France	38
CHU de Nantes	Nantes	France	60
CHU de Nice	Nice	France	51
CHU de Rennes	Rennes	France	32
CHU de Tours	Tours	France	16
CHU Dijon	Dijon	France	37
CHU Henri Mondor	Créteil	France	18
CHU Saint-Eloi - CHU de Montpellier	Montpellier	France	1
CHU Toulouse	Toulouse	France	76
Groupe Hospitalier Bretagne Sud	Lorient	France	6
Hopital de Hautepierre	Strasbourg	France	2

Clinical trials